David Rawling is a Product Development Scientist currently serving as a Principal Scientist at Precede Biosciences. They previously held roles such as Senior Scientist, Principal Scientist, and Director of Assay R&D at Inflammatix, Inc., where they were responsible for assay development and optimization. Earlier in their career, they worked as a Postdoctoral Scientist at Cepheid, focusing on mutational analysis assays in oncology, and as a Laboratory Technician at the University of Utah, where they conducted high-throughput protein studies. David is currently pursuing a Doctor of Philosophy in Molecular Biophysics and Biochemistry at Yale University and holds an Honors S.B. in Biochemistry and Chemistry from the University of Chicago.